智通财经APP获悉，据药明生物(02269)1月13日最新公司公告显示，2024年新增综合项目数为151个，项目总数达到817个，创多个历史新高， 彰显公司强劲的业务势头和持续增长的能力。
截至目前，研究服务项目已达50+个，多年深耕后迎腾飞拐点，通过合作推动创新，打开收入与利润增长的新空间；2024年新签148个开发项目，收入持续增长，通过卓越的执行力和快速交付，加速了项目推进；公司现有87个临床三期和商业化项目，为未来业务增长注入强大动能。2024年完成16个PPQ， 2025年预计有24个PPQ，收入将较2024年实现加速增长。增长强劲超预期，价值洼地可修复。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.